|
Total high-grade salivary gland cancers (n = 124)
|
|
Age [years; median (range)]
|
61 (31–89)
| |
|
Gender (Male/Female)
|
95/29
|
76.6/23.4
|
|
Tumor site
|
|
Parotid gland
|
84
|
67.7
|
|
Submandibular gland
|
38
|
30.6
|
|
Sublingual gland and minor salivary gland
|
2
|
1.6
|
|
T classification
|
|
T1
|
20
|
16.1
|
|
T2
|
44
|
35.5
|
|
T3
|
23
|
18.5
|
|
T4
|
37
|
29.8
|
|
N classification
|
|
N0
|
63
|
50.8
|
|
N1
|
10
|
8.1
|
|
N2–3
|
51
|
41.1
|
|
M classification
|
|
M0
|
109
|
87.9
|
|
M1
|
15
|
12.1
|
|
AJCC TNM stage
|
|
I
|
14
|
11.3
|
|
II
|
24
|
19.4
|
|
III
|
16
|
12.9
|
|
IV
|
70
|
56.5
|
|
Pathological diagnosis
|
|
Salivary duct carcinoma
|
74
|
59.7
|
|
Squamous cell carcinoma, primary*
|
13
|
10.5
|
|
Adenoid cystic carcinoma, solid type
|
12
|
9.7
|
|
Mucoepidermoid carcinoma, high-grade
|
9
|
7.3
|
|
Adenocarcinoma, high-grade
|
6
|
4.8
|
|
Atypical high-grade carcinoma
|
3
|
2.4
|
|
Carcino-sarcoma, high-grade
|
4
|
3.2
|
|
Poorly differentiated carcinoma
|
3
|
2.4
|
|
Treatment modalities
|
|
Surgery alone
|
13
|
10.5
|
|
Surgery + adjuvant radiation
|
62
|
50.0
|
|
Surgery + adjuvant radiation + chemotherapy
|
28
|
22.6
|
|
Initial non-surgical local treatment (radiation or chemoradiation)
|
3
|
2.4
|
|
Chemotherapy or palliative treatment
|
18
|
14.5
|
|
Clinical outcomes
|
|
Disease-specific death
|
39
|
31.5
|
|
Event-free follow-up period [months; median (range)]
|
109 [2–188]
| |
|
All-cause death
|
44
|
35.5
|
|
Resectable high-grade salivary gland caners (n = 103)
|
|
Surgery for primary tumor
|
|
R0 resection (cancer cells absent at the resection margin)
|
97
|
94.2
|
|
R1 resection (cancer cells present at the resection margin)
|
6
|
5.8
|
|
Neck dissection
|
|
No
|
31
|
30.1
|
|
Selective neck lymph node dissection
|
30
|
29.1
|
|
Comprehensive neck lymph node dissection
|
42
|
40.8
|
|
Pathological risk factors
|
|
Perineural invasion (Y/N)
|
13/90
|
12.6/87.4
|
|
Lymphovascular invasion (Y/N)
|
16/87
|
15.5/84.5
|
|
Extra-parenchymal (Extra-glandular) extension of tumor (Y/N)
|
45/58
|
43.7/56.3
|
|
Extra-capsular spread of lymph node metastasis (Y/N)
|
26/77
|
25.2/74.8
|
|
Clinical outcomes
|
|
Recurrence
|
40
|
38.8
|
|
Recurrence-free period [months; median (range)]
|
109 [2–188]
| |
|
Disease-specific death
|
27
|
26.2
|
|
Event-free follow-up period [months; median (range)]
|
123 [2–188]
| |
